Corvus Pharmaceuticals Inc

Slēgts

15.21 -0.26

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

14.77

Max

15.25

Galvenie mērījumi

By Trading Economics

Ienākumi

-1.4M

-14M

EPS

-0.15

Darbinieki

37

EBITDA

312K

-12M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+107.49% upside

Dividendes

By Acuity

Nākamie ieņēmumi

2026. g. 6. aug.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-199M

1.1B

Iepriekšējā atvēršanas cena

15.47

Iepriekšējā slēgšanas cena

15.21

Corvus Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 5. jūl. 23:51 UTC

Bitcoin and Ethereum rise as weak U.S. jobs data dims Fed rate hike expectations, while Asian markets react positively to easing geopolitical tensions.

2026. g. 5. jūl. 23:51 UTC

Bitcoin and Ethereum see positive returns amid weak U.S. jobs data and stable Eurozone activity, while geopolitical tensions ease.

2026. g. 5. jūl. 23:51 UTC

Bitcoin and Ethereum rise as U.S. jobs data dims Fed rate hike expectations ahead of key FOMC minutes release.

2026. g. 5. jūl. 23:51 UTC

Disappointing U.S. jobs report dampens interest rate hike expectations, impacting investor sentiment and market stability ahead of key economic releases.

2026. g. 5. jūl. 23:51 UTC

ISM Services PMI Forecasted at 54.2 Indicates Continued Growth Amid Economic Uncertainties and Potential Fed Policy Shifts

2026. g. 5. jūl. 23:51 UTC

Correlated Moves

Bitcoin is trading higher during Sunday’s session, continuing its upward trajectory since Saturday's close. The asset remains above its 20-day moving average.

2026. g. 5. jūl. 23:41 UTC

Canada's Full-Time Employment Change Data Release on July 10 Sparks Market Focus Amid Economic Uncertainty and Government Initiatives.

2026. g. 5. jūl. 23:41 UTC

Canada's Part-Time Employment Change Data Release on July 10, 2026, Could Signal Economic Health Amid Government Policy Announcements.

2026. g. 5. jūl. 23:41 UTC

Canada's unemployment rate data release on July 10, 2026, expected to show slight improvement at 6.6%, amid mixed signals in job growth and inflation concerns impacting monetary policy.

2026. g. 5. jūl. 23:41 UTC

Canada's Employment Change Report Forecasts 10,000 Job Increase Amid Mixed Market Sentiment and Economic Challenges

2026. g. 5. jūl. 23:41 UTC

Canada's Labor Force Participation Rate Release Amid Growing Concerns Over Job Security Due to AI and Automation

2026. g. 5. jūl. 23:31 UTC

Macro News
Correlated Moves

Silver prices are rising, supported by a recovery in gold and recent oil supply increases. The U.S. dollar's strength may limit upward momentum.

2026. g. 5. jūl. 23:31 UTC

Correlated Moves

XRP is trading roughly flat amid broader market sentiment, with Bitcoin moving moderately. The cumulative price change since Saturday remains minimal.

2026. g. 5. jūl. 23:22 UTC

U.S. Exports Data Release on July 7, 2026, Expected to Reflect Strong Performance Amid Trade Tensions and Inflationary Pressures

2026. g. 5. jūl. 23:22 UTC

U.S. Balance of Trade report on July 7 forecasts a $78.8 billion deficit, raising concerns over persistent trade imbalances and potential impacts on monetary policy amid cautious market sentiment.

2026. g. 5. jūl. 23:22 UTC

U.S. Imports Data Release on July 7 Expected to Show Continued Growth Amid Tariff Impacts and Supply Chain Adjustments

2026. g. 5. jūl. 23:22 UTC

Brazil's July 10 inflation rate release draws market attention amid global economic concerns and potential volatility.

2026. g. 5. jūl. 23:22 UTC

Mexico's July Inflation Rate Release Expected to Show Stabilization Around 3.94%, Influencing Future Banxico Policy Decisions

2026. g. 5. jūl. 23:22 UTC

Brazil's June Inflation Rate Expected to Rise, Heightening Market Volatility Ahead of July 10 Release

2026. g. 5. jūl. 23:22 UTC

Mexico's June Inflation Rate Release on July 9 Expected to Influence Monetary Policy Amid Global Economic Concerns.

2026. g. 5. jūl. 23:22 UTC

Canada's Balance of Trade data set for July 7, 2026, anticipates a C$2.4 billion surplus amid strong export activity and cautious optimism despite global uncertainties.

2026. g. 5. jūl. 23:11 UTC

USD/HKD is trading roughly flat after-market, with no specific news identified. Anticipation surrounds upcoming FOMC minutes and inflation data.

2026. g. 5. jūl. 23:02 UTC

Macro News
Correlated Moves

The U.S. dollar has recovered against the Canadian dollar, leading to a slight gain in USD/CAD after-market trading.

2026. g. 5. jūl. 23:02 UTC

Gold and silver are trading lower during Sunday’s session, continuing a downward trend since Friday's close. Market participants await key economic data.

2026. g. 5. jūl. 23:01 UTC

Correlated Moves

Silver/AUD is trading higher, supported by gold's gains and reduced interest rate hike expectations following weaker job growth data.

2026. g. 5. jūl. 23:01 UTC

Correlated Moves

Gold/NZD is trading higher, supported by rising gold prices against the U.S. dollar and market volatility ahead of key economic data releases.

2026. g. 5. jūl. 23:01 UTC

Correlated Moves

Silver/GBP is trading higher, reflecting gains in gold prices. The recent trend includes four consecutive sessions of closing higher.

2026. g. 5. jūl. 23:01 UTC

Correlated Moves

Silver/CHF is trading higher, reflecting gains from correlated movements in gold. The upward trend continues after four consecutive sessions of increases.

2026. g. 5. jūl. 23:01 UTC

Correlated Moves

Gold/HKD is higher, supported by positive market sentiment and a rise in silver. Weaker job growth data has reduced expectations for immediate interest rate hikes.

2026. g. 5. jūl. 23:01 UTC

Correlated Moves

Silver/CAD is higher, reflecting gains alongside rising gold prices. The asset has seen four consecutive sessions of higher closes amid significant volatility.

Salīdzinājums

Cenas izmaiņa

Corvus Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

107.49% augšup

Prognoze 12 mēnešiem

Vidējais 31.6 USD  107.49%

Augstākais 40 USD

Zemākais 27 USD

Pamatojoties uz 5 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Corvus Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

5 ratings

5

Pirkt

0

Turēt

0

Pārdot

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.
help-icon Live chat